Shenyang Dashan Pharmaceutical

Shenyang Dasan Pharmaceutical Technology Co., Ltd. (also known as Shenyang Dasan Labs) is a high-tech pharmaceutical R&D and CRO/CDMO company based in Shenyang, China. Founded in 2014, the company became a Sino-Korean joint venture in 2020 following a strategic investment from South Korea's Dasan Pharmaceutical. The company specializes in the development and industrialization of oral complex preparations, utilizing advanced drug delivery system (DDS) platforms such as powder coating taste masking and sustained/controlled-release pellet technologies. Shenyang Dasan provides a full suite of services including pharmaceutical preparation technology development, consistency evaluation, clinical trial services, and import drug registration. Its pipeline includes collaborations on Pelubiprofen (a COX inhibitor for pain and osteoarthritis) and PEG-3350 (for chronic constipation).